Atticus Pharma Inc
Publicly observedGreenville, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Greenville | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Atticus Pharma Inc | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | LZXUMNXR3AB5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant25 Sept 2026Publicly observed
NIH SBIR/STTR award: Phase 2: Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus
USD 1,007,121.00 · National Institute of Arthritis and Musculoskeletal and Skin Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2022Publicly observed
NIH SBIR/STTR award: Phase II: Optimization of a nanoparticle-based topical PDE5i formulation for treatment of erectile dysfunction
USD 965,708.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.